It's called "microfluidics array," and it tests human proteins for various genetic markers. Nuclea Biomarkers President Patrick Muraca said this technology uses a person's genetic makeup to find out if a cancer drug will work.

Muraca said, "What's revolutionary about this new technology is that we're helping pharmaceutical companies determine which patients will respond to their specific drugs."

And, there's lots of money to be made. One microfluidics array with protein samples sells for about $20,000.

Aside from being pioneers in the field of cancer research, this company is also adding some high-paying jobs to the area, and Muraca said there's more to come.

Muraca said, "The future is that this company is growing quite quickly. We've opened an office in Boston, Massachusetts. We've started a subsidiary in Worchester that will eventually be moving to Pittsfield."

Workers at the company said Pittsfield has welcomed the first bio-tech company in Western Massachusetts.

Senior Histologist Tad Sosnoski said, "There's economic support here, and the founding fathers come from here, and that's a big part of it."

Sosnoski said he's excited about upcoming projects that will change the way cancer is treated.

Sosnoski added, "We will be working with some very large pharmaceutical organizations, research groups, and universities. I know we're working with Dana Farber and a few others right now."

Nuclea Biomarkers will begin using the new technology next month.